Exploring Microbiome–Drug Synergies to Strengthen Mechanistic Evidence & Therapeutic Impact
- Present pilot data on combining Anaerobutyricum soehngenii with metformin to enhance glycemic control and reduce blood pressure in type 2 diabetes
- Evaluate how microbial therapies can mitigate drug-induced microbiota disruption and amplify host metabolic responses
- Discuss future directions for combination strategies, including prebiotics and multistrain consortia, and how spatial insights could support mechanistic understanding